LSTA:NASDAQ
Lisata Therapeutics Inc
၃.၄၇ US$
၀.၀၀%
(၀.၀၀) 1D
၃.၄၇ US$
၀.၀၀% (၀.၀၀)
bedtimeAfter hours
Closed: ဇွန် ၂၃, GMT-၄ ၁၆:၀၀:၀၁ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSTA...
Open
၃.၄၂ US$
High
၃.၅၀ US$
Low
၃.၄၂ US$
Mkt. cap
၃.၁၆ ကုဋေ
Avg. vol.
၁.၅၈ သိန်း
Volume
၀.၀၀
52-wk high
၅.၀၆ US$
52-wk low
၁.၈၁ US$
EPS
-၁.၈၆ US$
Beta
၀.၈၁
Shares outstanding
၉.၁၁ သန်း
No. of employees
၂၁
Open
၃.၄၂ US$
High
၃.၅၀ US$
Low
၃.၄၂ US$
Mkt. cap
၃.၁၆ ကုဋေ
Avg. vol.
၁.၅၈ သိန်း
Volume
၀.၀၀
52-wk high
၅.၀၆ US$
52-wk low
၁.၈၁ US$
EPS
-၁.၈၆ US$
Beta
၀.၈၁
Shares outstanding
၉.၁၁ သန်း
No. of employees
၂၁
News stories
From sources across the web
FinSMEs
·
ပြီးခဲ့သည့် ၁ နာရီ
STARTRADER Lists SpaceX (SPCX) CFD Days After Historic Nasdaq Debut
富途牛牛
·
ပြီးခဲ့သည့် ၉ မိနစ်
Setting aside the noise of the tech stock selloff, Barclays and Stifel see strong earnings and a year-end S&P 500 target of 7,800.
TradingView
·
ပြီးခဲ့သည့် ၂၉ မိနစ်
SPX: S&P 500 Tumbles 1.5% as Chip-Wreck Slams Wall Street. Futures Perk Up.
CNBC
·
ပြီးခဲ့သည့် ၉ နာရီ
Alphabet added to Dow Jones Industrial Average, replacing Verizon
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics Inc
CEO-
Employees၂၁
Founded၁၉၈၀
HeadquartersBasking Ridge, နယူးဂျာစီပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitelisata.com
AI content may include mistakes. Learn more